Navigation Links
MGI in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

... Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including mgi Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services. "I have always known the substantial p...

Call for Nominations for the 2009 C.A.R.E. Pharmacy Award

...maceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion, including the results of the acquisition of mgi PHARMA, INC. Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical pro...

Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD)

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical p...

NewCardio Elects Michael E. Hanson to Board of Directors

...es, of GlycoGenesis, an oncology-focused company. From 1998 to 2001, he was a member of the board of directors, compensation and audit committees, of mgi Pharma, Inc., which was later purchased by Eisai Pharmaceuticals. Mr. Hanson also serves on the board of directors of Z-92 Pharma and Elcos, Inc., an...

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

...ursuant to the license agreement entered into with mgi PHARMA (acquired by Eisai Corporation of North America in January 2008) during 2004, which granted mgi PHARMA exclusive rights to the development, manufa...the license agreement previously entered into with mgi PHARMA. The Company recognizes royalty revenue on...

Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, INC. Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical...

Oncologists Rank Aloxi's Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market

...pared to other therapeutic areas," said Marcus Hoyle, analyst at Decision Resources. "In 2007 $61 million was spent by the leading competitors (Merck, mgi Pharma/Eisai, Roche and Sanofi-Aventis) in the United States to promote their respective brands." About Brands & Strategies The Br...

New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,800 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical product...

Eisai Inc. Supports Acting Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,800 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical product...

Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical product...
MGI in Medical Technology

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical p...

First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, Inc. Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical product...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

...pivotal Phase 3 study by SuperGen and partnered to mgi PHARMA, INC. (acquired by Eisai Co., Ltd.). mgi PHARMA subsequently sublicensed all Dacogen rights...llion, including the results of the acquisition of mgi PHARMA. For more information about Eisai, please v...

Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%

...odies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; mgi PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintain...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

...oducts. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired mgi PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology a...

AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients

...nce. The authors also report that combining Aviara mgi with Aviara H/I(SM) (HOXB13:IL17BR), a biomarker p... edition of Clinical Cancer Research. The Aviara mgi and Aviara H/I ("H over I") biomarkers measure spe...rom John Radcliffe Hospital, Oxford (UK). Aviara mgi is a new molecular assay comprising only five gene...

FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents

...odies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; mgi PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintain...

MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy

... MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - mgi PHARMA, INC. (NASDAQ: MOGN), a biopharmaceutical c...ndation of the Aquavan New Drug Application (NDA). mgi PHARMA plans to submit the Aquavan NDA to the U.S.... Moulder, President and Chief Executive Officer of mgi PHARMA. "The results of this pivotal program, toge...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

...rger Phase 2 trial is certainly warranted to evaluate efficacy." Dr. Brem is a developer of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant, mgi Pharma), the first approved local therapy for glioma. Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the pa...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

... MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- mgi PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical co...ive Vice President and Chief Scientific Officer of mgi PHARMA. "We are very pleased with the outcome of t...ration in the third quarter of this year." About mgi PHARMA ...
MGI in Biological News

Temple University Hospital investigates treatment for cervical dysplasia

...e moderate to severe cervical dysplasia, a precancerous condition," explained Hernandez. Amolimogene is an investigational immunotherapeutic from mgi PHARMA, Inc. that is currently being evaluated in a pivotal phase 2 clinical program in multiple centers in the U.S., including Philadelphia. "This pr...
MGI in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...Corporation II-69 GPC Biotech and Celgene Terminate Agreement for Satraplatin II-70 EUSA Acquires Cytogen Corporation II-70 Eisai Acquires mgi Pharma II-70 BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI II-70 Morphotek(R) Enters into Licensing Agreement with N...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...onsors Seminar on Acute Myelogenous Leukemia in Elderly Patients The Company is co-sponsoring a seminar at the Meeting, in conjunction with mgi Pharmaceuticals and the Geriatric Oncology Consortium, entitled "Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem." The se...

Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award

...armaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of mgi PHARMA, INC. Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical p...

SuperGen Reports 2008 Third Quarter Financial Results

...yalty revenue is earned pursuant to the license agreement entered into with mgi PHARMA (acquired by Eisai Co., Ltd. in January 2008) during 2004, which gra...yalty revenue is earned pursuant to the license agreement entered into with mgi PHARMA. The Company recognizes royalty revenue on a cash basis when it is r...

Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America

... a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including mgi Pharma, Amgen and Genentech. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radia...

Milestone Biosciences, LLC Further Strengthens Executive Management Team

...sident, Chief Operating Officer, General Counsel and Corporate Secretary of mgi PHARMA, INC., where he was responsible for MGI's commercial, medical affair..., government affairs, reimbursement and legal operations. Mr. Loukas joined mgi in July 2004 as Senior Vice President, General Counsel and Corporate Secret...

SuperGen Reports 2008 Second Quarter Financial Results

...ursuant to the license agreement entered into with mgi PHARMA (acquired by Eisai Co., Ltd. in January 2008) during 2004, which granted mgi PHARMA exclusive rights to the development, manufa...ursuant to the license agreement entered into with mgi PHARMA. The Company recognizes royalty revenue on ...

FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents

...odies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; mgi PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintain...

FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation

...poration of North America and its U.S. subsidiary, mgi PHARMA, INC., today announced that the U.S. Food a... with manufacturing and marketing/sales functions; mgi PHARMA, INC.; and Eisai Machinery U.S.A., which ma...isai, please visit http://www.eisai.com . About mgi PHARMA, INC. ...

Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.

... to our company. She will be instrumental in driving Eisai's integration of mgi PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutica...., a commercial operation with manufacturing and marketing/sales functions; mgi PHARMA, Inc., an R&D and commercial operation with manufacturing and market...
MGI in Biological Dictionary

Deoxyribonuclease

...that catalyzes the ... Deoxyribonuclease I edit Deoxyribonuclease I Identifiers Symbols DNASE1 ; DNL1; DRNI; FLJ38093 External IDs OMIM: 125505 mgi : 103157 Definition of deoxyribonuclease from the Merriam-Webster Online Dictionary with audio pronunciations, thesaurus, Word of the Day, and wo...
Other Tags
(Date:7/12/2014)... 12, 2014 The rise in the ... for new advanced network architectures to suit the upsurge. ... industry with increasing cloud storage technologies. The data traffic ... more mobility devices. This has resulted in larger and ... driving forces for the SDN market. , The North ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... way to guarantee that a surgical technique used to grind ... increase the risk of spreading cancer to other parts of ... advisory panel to the Food and Drug Administration also said ... power morcellation -- should sign a written consent stating that ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
(Date:7/12/2014)... The Security Analytics market is estimated ... million by 2019, at an expected CAGR of 9.7% ... to counter the increasing number of security breaches, continued ... defense systems in organizations are enormous. Vendors in the ... existing architecture to develop better and more secure systems. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
(Date:7/10/2014)... 7, 2014 Fingerprint Cards, (FPC,s) new ... win (DW). A Chinese Top 5 smartphone OEM has selected ... mass production in October 2014.   FPC is ... smartphone OEM, which has a planned date for the start ... volume for this phone of 3 million units. The Chinese ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
Other Contents